| [1] |
Wang Y, Wang M, Liu C, et al. Global burden of liver cirrhosis 1990–2019 and 20 years forecast: results from the global burden of disease study 2019[J]. Ann Med, 2024, 56: 2328521. DOI: 10.1080/07853890.2024.2328521.
|
| [2] |
|
| [3] |
Wang G, Dong W, Zhang H, et al. Activation of MEK-ERK-c-MYC signaling pathway promotes splenic M2-like macrophage polarization to inhibit PHcH-liver cirrhosis[J]. Front Immunol, 2024, 15: 1417521. DOI: 10.3389/fimmu.2024.1417521.
|
| [4] |
|
| [5] |
Zakeri S, Gorji N, Akhtari M, et al. Splenectomy may have more complications than currently proven[J]. Med Hypotheses, 2018, 112: 43-46. DOI: 10.1016/j.mehy.2018.01.009.
|
| [6] |
Swinson B, Waters PS, Webber L, et al. Portal vein thrombosis following elective laparoscopic splenectomy: incidence and analysis of risk factors[J]. Surg Endosc, 2022, 36(5): 3332-3339. DOI: 10.1007/s00464-021-08649-x.
|
| [7] |
Yao W, Feng YA, Liu T, et al. Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: a randomized clinical trial[J]. EXCLI J, 2021, 20: 537-549. DOI: 10.17179/excli2020-3120.
|
| [8] |
Yang M, Liu J. Low-molecular weight heparin prevents portal vein system thrombosis after splenectomy: a systematic review and meta-analysis[J]. ANZ J Surg, 2020, 90(12): 2420-2424. DOI: 10.1111/ans.15865.
|
| [9] |
Li T, Wang LL, Li YP, et al. Predictors of portal vein thrombosis after splenectomy in patients with cirrhosis[J]. World J Hepatol, 2024, 16(2): 241-250. DOI: 10.4254/wjh.v16.i2.241.
|
| [10] |
Qu D, Dai D, Li G, et al. Development of an explainable prediction model for portal vein system thrombosis post-splenectomy in patients with cirrhosis[J]. BMJ Health Care Inform, 2025, 32(1): e101319. DOI: 10.1136/bmjhci-2024-101319.
|
| [11] |
Lin YK, Cai XR, Hong HJ, et al. Risk factors of portal vein system thrombosis after splenectomy: a meta-analysis[J]. ANZ J Surg, 2023, 93(12): 2806-2819. DOI: 10.1111/ans.18633.
|
| [12] |
Gao H, Sun B, Li X, et al. Risk factors for portal vein system thrombosis after partial splenic embolisation in cirrhotic patients with hypersplenism[J]. Clin Radiol, 2023, 78(12): 919-927. DOI: 10.1016/j.crad.2023.07.022.
|
| [13] |
Baldari L, Boni L, Giuliani B, et al. Porto-spleno-mesenteric venous thrombosis after elective splenectomy: a retrospective cohort study[J]. Front Immunol, 2023, 14: 1216283. DOI: 10.3389/fimmu.2023.1216283.
|
| [14] |
Li Y, Fu X, Li Y, et al. Early prevention and risk factors analysis of portal vein system thrombosis after laparoscopic splenectomy and pericardial devascularization[J]. Surg Endosc, 2022, 36(12): 8918-8926. DOI: 10.1007/s00464-022-09340-5.
|
| [15] |
Arnold P, Belchos J, Meagher A, et al. Postoperative pancreatic fistula following traumatic splenectomy: a morbid and costly complication[J]. J Surg Res, 2022, 280: 35-43. DOI: 10.1016/j.jss.2022.07.005.
|
| [16] |
Huang L, Yu Q, Peng H, et al. Postoperative outcomes following a modified method of surgical division of the splenic pedicle in 719 patients during splenectomy for portal hypertension: a 12-year, retrospective, single-center study[J]. Med Sci Monit, 2022, 28: e937763. DOI: 10.12659/msm.937763.
|
| [17] |
Zhu JM, Chen G, Jiao ZY. Non-operative treatment of gastric fistula after splenectomy combined with pericardial devascularisation in portal hypertension[J]. J Coll Physicians Surg Pak, 2021, 31(3): 334-336. DOI: 10.29271/jcpsp.2021.03.334.
|
| [18] |
Qu Y, Ren S, Li C, et al. Management of postoperative complications following splenectomy[J]. Int Surg, 2013, 98(1): 55-60. DOI: 10.9738/cc63.1.
|
| [19] |
Al Kahf S, Roche A, Baron A, et al. Pulmonary hypertension in sickle cell disease[J]. La Presse Médicale, 2023, 52(4): 104209. DOI: 10.1016/j.lpm.2023.104209.
|
| [20] |
Feld JJ, Kato GJ, Koh C, et al. Liver injury is associated with mortality in sickle cell disease[J]. Aliment Pharmacol Ther, 2015, 42(7): 912-921. DOI: 10.1111/apt.13347.
|
| [21] |
El-Gohary Y, Fleming A, Zhang H, et al. Acute chest syndrome after splenectomy in children with sickle cell disease[J]. J Surg Res, 2019, 242: 336-341. DOI: 10.1016/j.jss.2019.04.077.
|
| [22] |
Koehl JL, Koyfman A, Hayes BD, et al. High risk and low prevalence diseases: acute chest syndrome in sickle cell disease[J]. Am J Emerg Med, 2022, 58: 235-244. DOI: 10.1016/j.ajem.2022.06.018.
|
| [23] |
Tahir F, Ahmed J, Malik F. Post-splenectomy sepsis: a review of the literature[J]. Cureus, 2020, 12(2): e6898. DOI: 10.7759/cureus.6898.
|
| [24] |
Luu S, Spelman D, Woolley IJ. Post-splenectomy sepsis: preventative strategies, challenges, and solutions[J]. Infect Drug Resist, 2019, 12: 2839-2851. DOI: 10.2147/idr.s179902.
|
| [25] |
Sun LM, Chen HJ, Jeng LB, et al. Splenectomy and increased subsequent cancer risk: a nationwide population-based cohort study[J]. Am J Surg, 2015, 210(2): 243-251. DOI: 10.1016/j.amjsurg.2015.01.017.
|
| [26] |
Kristinsson SY, Gridley G, Hoover RN, et al. Long-term risks after splenectomy among 8, 149 cancer-free American veterans: a cohort study with up to 27 years follow-up[J]. Haematologica, 2014, 99(2): 392-398. DOI: 10.3324/haematol.2013.092460.
|
| [27] |
|
| [28] |
Ai XM, Ho LC, Han LL, et al. The role of splenectomy in lipid metabolism and atherosclerosis (AS)[J]. Lipds Health Dis, 2018, 17(1): 186. DOI: 10.1186/s12944-018-0841-2.
|
| [29] |
Gunes O, Turgut E, Bag YM, et al. The impact of splenectomy on human lipid metabolism[J]. Ups J Med Sci, 2022, 127. DOI: 10.48101/ujms.v127.8500.
|
| [30] |
Tsai MS, Chou SE, Lai HS, et al. Long-term risk of acute coronary syndrome in splenectomized patients due to splenic injury[J]. Medicine, 2015, 94(9): e610. DOI: 10.1097/md.0000000000000610.
|
| [31] |
Ejikeme C, Elkattawy S, Kayode-Ajala F, et al. Reactive thrombocytosis after splenectomy in hereditary spherocytosis: case report and literature review[J]. Eur J Case Rep Intern Med, 2021, 8(7): 21. DOI: 10.12890/2021_002673.
|
| [32] |
Luu S, Woolley IJ, Andrews RK. Platelet phenotype and function in the absence of splenic sequestration (Review)[J]. Platelets, 2021, 32(1): 47-52. DOI: 10.1080/09537104.2020.1732322.
|
| [33] |
Bollova D, Reptova A, Valkovicova T, et al. Risk of chronic thromboembolic pulmonary hypertension after splenectomy[J]. Bratislava Med J, 2024, 125(3): 176-182. DOI: 10.4149/bll_2024_28.
|
| [34] |
Huang L, Li W, Yang T, et al. Association between splenectomy and portal hypertension in the development of pulmonary hypertension[J]. Pulm Circ, 2020, 10(1): 1-9. DOI: 10.1177/2045894019895426.
|
| [35] |
Hsu CY, Chen HJ, Hsu CY, et al. Splenectomy increases the subsequent risk of systemic lupus erythematosus[J]. Rheumatol Int, 2016, 36(2): 271-276. DOI: 10.1007/s00296-015-3388-9.
|
| [36] |
Ambler WG, Kaplan MJ. Vascular damage in systemic lupus erythematosus[J]. Nat Rev Nephrol, 2024, 20(4): 251-265. DOI: 10.1038/s41581-023-00797-8.
|
| [37] |
Wu SC, Fu CY, Muo CH, et al. Splenectomy in trauma patients is associated with an increased risk of postoperative type Ⅱ diabetes: a nationwide population-based study[J]. Am J Surg, 2014, 208(5): 811-816. DOI: 10.1016/j.amjsurg.2014.03.003.
|
| [38] |
Haile M, Boutajangout A, Chung K, et al. The Cox-2 inhibitor meloxicam ameliorates neuroinflammation and depressive behavior in adult mice after splenectomy[J]. J Neurophysiol Neurol Disord, 2016, 3: 101.
|
| [39] |
Xiao W, Yang X, Wang Y, et al. Splenectomy delays fracture healing by affecting the level of tumor necrosis factor alpha, interleukin 6 and bone morphogenetic protein[J]. Adv Clin Exp Med, 2018, 27(2): 165-171. DOI: 10.17219/acem/67755.
|
| [40] |
Ni F, Zhang T, Xiao W, et al. IL-18-mediated SLC7A5 overexpression enhances osteogenic differentiation of human bone marrow mesenchymal stem cells via the c-MYC pathway[J]. Front Cell Dev Biol, 2021, 9: 748831. DOI: 10.3389/fcell.2021.748831.
|